Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines
Questions and concerns regarding the efficacy and immunogenicity of coronavirus disease 2019 (COVID-19) vaccines have plagued scientists since the BNT162b2 mRNA vaccine was introduced in late 2020. As a result, decisions about vaccine boosters based on breakthrough infection rates and the decline of...
Main Authors: | Mohammad Reza Sepand, Banafsheh Bigdelou, Jim Q. Ho, Mohammad Sharaf, Alexis J. Lannigan, Ian M. Sullivan, Alecsander P. da Silva, Leland O. Barrett, Scott McGoldrick, Yuvraj Lnu, Shannon E. Lynch, Jared M. Boisclair, Dakarai D. Barnard-Pratt, Steven Zanganeh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/11/2/35 |
Similar Items
-
Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
by: Kathleen P. Pratt
Published: (2018-05-01) -
Bacterial Immunogenicity Prediction by Machine Learning Methods
by: Ivan Dimitrov, et al.
Published: (2020-11-01) -
The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01) -
Ferroptosis: friend or foe in cancer immunotherapy?
by: Robin Demuynck, et al.
Published: (2023-12-01) -
OVERVIEW OF PRE-CLINICAL TECHNIQUES FOR PREDICTING THE IMMUNOGENICITY OF THERAPEUTICS IN DRUG DEVELOPEMENT
by: Clarisse Musanabaganwa, et al.
Published: (2014-03-01)